Atrial fibrillation (AF) is a common arrhythmia which carries a significant risk of stroke.
Secondary prevention, particularly in the acute phase of stroke with anti-thrombotic therapy …

Background. Cardioembolic stroke secondary to atrial fibrillation (AF) accounts for 1.5%-
23.5% of all ischaemic strokes. Patients with prior stroke or transient ischaemic attack (TIA) …

Antithrombotics have been shown to decrease the risk of stroke in patients with atrial
fibrillation (AF). However they are associated with an increased risk of bleeding. We …

Patients with ischemic stroke or transient ischemic attack and non-valvular atrial fibrillation
have a high risk of recurrent stroke and other vascular events. The aim of this guideline is to …

For over two decades, valuable insights have been accumulated from epidemiologic studies
and randomized trials about the risks and prevention of atrial fibrillation. Atrial fibrillation (AF) …

Cerebrovascular disease can be devastating for patients and their families, but much can be
done to attenuate cerebral damage and reduce disability. Active intervention is in three …

Aim of this article is to present the state-of-the-art antithrombotic therapy for the secondary
prevention of cardioembolic stroke due to new ESC, ACC, and ACCP guidelines which are …

Background Atrial fibrillation (AF) is the most common cardiac dysrhythmia, with a lifetime
risk of 25%, and it is a well-known independent risk factor for ischemic stroke. Over the last …

Primary and secondary prevention of stroke is often a challenge in elderly patients due to
the increase in both thrombotic and hemorrhagic risks with age. In some cases, there is …

Aims Long-term oral anticoagulant (LTOAC) reduces ischaemic stroke recurrences.
Because of bleeding history, frailty, cognitive impairment, comorbidities or patient refusal …